LifeStance Health Group (NASDAQ:LFST) Director Robert Bessler Sells 6,442 Shares

by · The Cerbat Gem

LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) Director Robert Bessler sold 6,442 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.00, for a total value of $45,094.00. Following the completion of the transaction, the director directly owned 1,378,954 shares in the company, valued at $9,652,678. This trade represents a 0.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Bessler also recently made the following trade(s):

  • On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total value of $86,597.00.
  • On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total value of $558,206.30.

LifeStance Health Group Stock Up 1.6%

NASDAQ LFST traded up $0.11 on Friday, reaching $7.05. The company had a trading volume of 9,306,414 shares, compared to its average volume of 2,042,345. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58. LifeStance Health Group, Inc. has a 1 year low of $3.74 and a 1 year high of $8.30. The firm has a 50-day moving average of $5.95 and a 200-day moving average of $5.37. The firm has a market capitalization of $2.74 billion, a PE ratio of -235.00 and a beta of 1.13.

LifeStance Health Group (NASDAQ:LFST – Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. The business had revenue of $363.81 million for the quarter, compared to analysts’ expectations of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The business’s revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.02) earnings per share. On average, equities research analysts anticipate that LifeStance Health Group, Inc. will post -0.18 EPS for the current fiscal year.

Hedge Funds Weigh In On LifeStance Health Group

A number of hedge funds have recently added to or reduced their stakes in LFST. Tudor Investment Corp ET AL acquired a new stake in shares of LifeStance Health Group during the third quarter worth $1,040,000. CIBC Bancorp USA Inc. bought a new stake in shares of LifeStance Health Group during the 3rd quarter valued at about $78,000. Jacobs Levy Equity Management Inc. raised its stake in LifeStance Health Group by 1.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,147,690 shares of the company’s stock worth $11,812,000 after acquiring an additional 38,528 shares during the period. Dark Forest Capital Management LP acquired a new stake in LifeStance Health Group during the third quarter worth about $140,000. Finally, PharVision Advisers LLC bought a new position in LifeStance Health Group in the third quarter worth about $84,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

Wall Street Analysts Forecast Growth

LFST has been the topic of a number of analyst reports. BMO Capital Markets started coverage on LifeStance Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $8.00 target price on the stock. Wall Street Zen downgraded LifeStance Health Group from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Barclays assumed coverage on LifeStance Health Group in a research note on Tuesday, December 9th. They set an “overweight” rating and a $8.00 target price for the company. BTIG Research raised their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

Check Out Our Latest Analysis on LifeStance Health Group

LifeStance Health Group Company Profile

(Get Free Report)

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

See Also